Matthews International Capital Management LLC Buys 73,200 Shares of Schrödinger, Inc. (NASDAQ:SDGR)


Share on StockTwits

Matthews International Capital Management LLC grew its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 26.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 352,900 shares of the company’s stock after purchasing an additional 73,200 shares during the period. Schrödinger makes up about 1.5% of Matthews International Capital Management LLC’s portfolio, making the stock its 20th biggest holding. Matthews International Capital Management LLC owned about 0.51% of Schrödinger worth $27,943,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of SDGR. Aurora Investment Managers LLC. purchased a new stake in shares of Schrödinger during the 3rd quarter valued at $2,462,000. DekaBank Deutsche Girozentrale lifted its holdings in shares of Schrödinger by 54.0% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 38,800 shares of the company’s stock valued at $1,845,000 after purchasing an additional 13,600 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Schrödinger during the 3rd quarter valued at $808,000. Amalgamated Bank lifted its holdings in shares of Schrödinger by 106.0% during the 3rd quarter. Amalgamated Bank now owns 4,537 shares of the company’s stock valued at $216,000 after purchasing an additional 2,335 shares during the last quarter. Finally, ARK Investment Management LLC lifted its holdings in shares of Schrödinger by 232.5% during the 3rd quarter. ARK Investment Management LLC now owns 517,035 shares of the company’s stock valued at $24,564,000 after purchasing an additional 361,519 shares during the last quarter. Hedge funds and other institutional investors own 41.29% of the company’s stock.

NASDAQ SDGR opened at $104.21 on Tuesday. The stock has a 50-day simple moving average of $95.77 and a two-hundred day simple moving average of $70.53. Schrödinger, Inc. has a fifty-two week low of $27.04 and a fifty-two week high of $117.00.

In related news, major shareholder David E. Shaw sold 45,000 shares of Schrödinger stock in a transaction dated Wednesday, February 17th. The stock was sold at an average price of $104.82, for a total value of $4,716,900.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder David E. Shaw sold 72,367 shares of Schrödinger stock in a transaction dated Friday, February 19th. The stock was sold at an average price of $104.83, for a total value of $7,586,232.61. The disclosure for this sale can be found here. Insiders have sold a total of 807,369 shares of company stock worth $59,758,858 over the last 90 days.

Several analysts have recently commented on SDGR shares. Bank of America upgraded Schrödinger from a “neutral” rating to a “buy” rating and set a $74.00 price objective for the company in a report on Monday, November 23rd. Morgan Stanley reduced their target price on Schrödinger from $90.00 to $89.00 and set an “equal weight” rating for the company in a research note on Friday, November 13th. BMO Capital Markets raised their target price on Schrödinger from $97.00 to $117.00 and gave the stock an “outperform” rating in a research note on Monday, January 25th. Finally, Zacks Investment Research lowered Schrödinger from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $89.60.

Schrödinger Company Profile

Schrödinger, Inc provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.

Read More: What are the benefits of investing in REITs?

Institutional Ownership by Quarter for Schrödinger (NASDAQ:SDGR)

Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.